Fig. 5.

Simulated time courses of plasma emicizumab concentration at the selected phase III dosing regimens of a repeated subcutaneous loading dose of 3 mg/kg once weekly for first 4 weeks followed by subcutaneous maintenance doses of 1.5 mg/kg once weekly (a), 3 mg/kg every 2 weeks (b), and 6 mg/kg every 4 weeks (c). Solid line indicates the simulated median profile, open circles indicate the simulated median trough concentrations, shaded area indicates the simulated 5th to 95th percentile range, and dashed line indicates the target efficacious exposure of 45 μg/mL